Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
48 hedge funds and large institutions have $78.7M invested in Concert Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
32.76% more ownership
Funds ownership: 0% → 32.76% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$16.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$9.7M |
| 3 |
DM
Deerfield Management
New York
|
+$8.72M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.2M |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
+$4.53M |
Top Sellers
CNCE Hedge Fund Activity: Q1 2014 in Review
48 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2014, worth a combined $78.7M.
Buyers outnumbered sellers: 48 funds opened new CNCE positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bain Capital Public Equity Management, opening a new position worth an estimated $16.2M.
- 48 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $78.7M of Concert Pharmaceuticals, Inc. stock for Q1 2014.
- 48 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2014 and 0 closed out, a net change of +48 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2014 was Bain Capital Public Equity Management, an estimated $16.2M added.
Based on aggregated 13F filings for Q1 2014.